{"id":25,"date":"2021-04-16T13:18:56","date_gmt":"2021-04-16T13:18:56","guid":{"rendered":"https:\/\/dryamd.info\/?page_id=25"},"modified":"2026-05-06T13:57:03","modified_gmt":"2026-05-06T13:57:03","slug":"vivre-avec-la-dmla-atrophique","status":"publish","type":"page","link":"https:\/\/dryamd.info\/fr\/vivre-avec-la-dmla-atrophique\/","title":{"rendered":"Vivre avec la DMLA atrophique"},"content":{"rendered":"\n

VIVRE AVEC LA DMLA atrophique<\/strong><\/h1>\n\n\n\n

La pr\u00e9valence des maladies oculaires li\u00e9es \u00e0 l’\u00e2ge, notamment la DMLA s\u00e8che avanc\u00e9e ou DMLA atrophique, devrait augmenter dans les ann\u00e9es \u00e0 venir. Actuellement, cette maladie touche plus de 5 millions de personnes dans le monde, mais sa pr\u00e9valence devrait doubler dans les 20 prochaines ann\u00e9es pour atteindre plus de 10 millions de personnes.9<\/sup><\/strong><\/p>\n\n\n\n

Ce site est con\u00e7u pour fournir des informations et un soutien aux personnes touch\u00e9es par la DMLA s\u00e8che avanc\u00e9e ou DMLA atrophique, ainsi qu’\u00e0 ceux qui les soignent.<\/p>\n\n\n\n

L’infographie suivante pr\u00e9sente des faits et des informations cl\u00e9s sur la forme avanc\u00e9e de la DMLA s\u00e8che ou atrophie g\u00e9ographique. Nous avons cr\u00e9\u00e9 l’infographie dans un certain nombre de formats afin de nous assurer que nous r\u00e9pondons aux besoins des personnes souffrant de d\u00e9ficience visuelle. Les formats alternatifs peuvent \u00eatre t\u00e9l\u00e9charg\u00e9s ci-dessous.<\/p>\n\n\n\n

\n
\n
\n
T\u00c9L\u00c9CHARGER LA VERSION TEXTE DESCRIPTIVE POUR UTILISATION AVEC DES LECTEURS D’\u00c9CRAN (PDF)<\/strong><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n
\n
T\u00c9L\u00c9CHARGER LE PDF MULTI-COULEURS \u00c0 HAUT CONTRASTE<\/strong><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n
\n
T\u00c9L\u00c9CHARGER LA VERSION PDF DU FOND NOIR \u00c0 HAUT CONTRASTE<\/strong><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n
\n
T\u00c9L\u00c9CHARGER LA VERSION PDF DU FOND JAUNE \u00c0 HAUT CONTRASTE<\/strong><\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Helpful resources & links<\/strong><\/p>\n\n\n\n

\n
GLOSSAIRE<\/a><\/div>\n<\/div>\n\n\n\n


<\/p>\n\n\n\n



<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

R\u00e9f\u00e9rences:<\/p>\n\n\n\n

    \n
  1. Gehrs KM, et al. Ann Med. 2006;38(7):450-471.<\/li>\n\n\n\n
  2. Fleckenstein, M. et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 125, 369\u2013390 (2018).<\/li>\n\n\n\n
  3. Sivaprasad S, et al. Ophthalmol Ther. 2019;8:115-124<\/li>\n\n\n\n
  4. Kaszubski P, et al. Ophthalmic Res. 2016;55(4):185-193<\/li>\n\n\n\n
  5. Boyer, D. S., Schmidt-Erfurth, U., Van Lookeren Campagne, M., Henry, E. C. & Brittain, C. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina 37, 819\u2013835 (2017).<\/li>\n\n\n\n
  6. Young, R. W. Pathophysiology of age-related macular degeneration. Surv. Ophthalmol. 31, (1987).<\/li>\n\n\n\n
  7. EURETINA. Retinal Diseases in Europe. PDF file. Accessed Apr. 29, 2021.
    https:\/\/www.euretina.org\/downloads\/EURETINA_Retinal_Diseases.pdf<\/li>\n\n\n\n
  8. Age-Related Macular Degeneration: Facts & Figures. Bright Focus Foundation. Accessed Apr. 29, 2021. https:\/\/www.brightfocus.org\/macular\/article\/age-related-macular-facts-figures<\/li>\n\n\n\n
  9. Wong WL, et al. Lancet Glob Health. 2014;2:e106-116.<\/li>\n\n\n\n
  10. What is Geographic Atrophy? Bright Focus Foundation. Accessed Apr. 29, 2021. https:\/\/www.brightfocus.org\/macular\/article\/what-geographic-atrophy<\/li>\n\n\n\n
  11. Ardeljan, D. & Chan, C. C. Aging is not a disease: Distinguishing age-related macular degeneration from aging. Progress in Retinal and Eye Research (2013) doi:10.1016\/j.preteyeres.2013.07.003.<\/li>\n\n\n\n
  12. Bear, M., Connors, B. & Paradiso, M. Neuroscience: Exploring the Brain (Third Edition). Library (Lond). (2006) doi:10.1007\/BF02234670.<\/li>\n\n\n\n
  13. Bonnel, S., Mohand-Said, S. & Sahel, J. A. The aging of the retina. Exp. Gerontol. (2003) doi:10.1016\/S0531-5565(03)00093-7.<\/li>\n\n\n\n
  14. Pennington, K. L. & DeAngelis, M. M. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis. 3, (2016).<\/li>\n\n\n\n
  15. Patel PJ, et al. Clin Ophthalmol. 2020;15-28<\/li>\n<\/ol>\n\n\n\n

    EU-GA-2300004 May 2026<\/p>\n","protected":false},"excerpt":{"rendered":"

    VIVRE AVEC LA DMLA atrophique La pr\u00e9valence des maladies oculaires li\u00e9es \u00e0 l’\u00e2ge, notamment la DMLA s\u00e8che avanc\u00e9e ou DMLA atrophique, devrait augmenter dans les ann\u00e9es \u00e0 venir. Actuellement, cette maladie touche plus de 5 millions de personnes dans le monde, mais sa pr\u00e9valence devrait doubler dans les 20 prochaines ann\u00e9es pour atteindre plus de […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-25","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t